Skip to main content
Log on / register
Feedback
|
Support
|
My details
home
|
journals A-Z
|
subject areas
|
advanced search
|
authors
|
reviewers
|
libraries
|
jobs
|
about
|
my BioMed Central
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
Papp KA, Toth D, Rosoph L
BMC Dermatol
2006,
6
:9
[
Full text
]
[
PubMed
]
[
Related articles
]
No citations for this article were found in PubMed Central.
Terms and Conditions
Privacy statement
Information for advertisers
Jobs at BMC
Contact us
© 1999-2008 BioMed Central Ltd unless otherwise stated
